Cellink AB: € 2.5M

The company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. Cellink was granted € 2.5M from the SME Instrument HORIZON 2020, phase 2.


“Collaborating with GAEU has been great! The team is very responsive, knowledgable, and supportive. Their work and efforts will help us ensure long term success. A company to depend on.”


Erik Gatenholm, CEO